Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Minocycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | USP2 | O75604 | 5/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.68 |
| ▸ | GRK6 | P43250 | 1/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | ALB | P02768 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Minocycline SCHEMBL5175145 | 1.00 | TDP1 (0.70) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL3969889 | 1.00 | TDP1 (0.70) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL3969884 | 1.00 | TDP1 (0.70) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL10477625 | 1.00 | TDP1 (0.70) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL10477623 | 1.00 | TDP1 (0.70) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL2537 | 0.99 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL1446032 | 0.99 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL2539 | 0.99 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL21524892 | 0.99 | TDP1 (0.69) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL2865953 | 0.99 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102617396-B | Minocycline hydrochloride hydrate crystal form and synthesis method thereof | UNIV ZHEJIANG | 2015-06-24 | — | — | CN | claimed |
| US-8642089-B2 | Melt extrusion of salts of active ingredients | EVONIK ROEHM GMBH (DE) | 2014-02-04 | — | — | US | claimed |
| CN-101693669-B | minocycline hydrochloride hydrate crystal form and preparation method thereof | UNIV ZHEJIANG | 2012-08-08 | — | — | CN | claimed |
| CN-102617396-A | Minocycline hydrochloride hydrate crystal form and synthesis method thereof | UNIV ZHEJIANG | 2012-08-01 | — | — | CN | claimed |
| CN-101693669-A | Minocycline hydrochloride hydrate crystal form and preparation method thereof | UNIV ZHEJIANG | 2010-04-14 | — | — | CN | claimed |
| EP-1478344-B1 | MELT EXTRUSION CONSISTING OF SALTS OF ACTIVE INGREDIENTS | ROEHM GMBH (DE) | 2007-05-23 | — | — | EP | claimed |
| US-20040253314-A1 | Melt extrusion of salts of active ingredients | ROEHM GMBH (DE) | 2004-12-16 | — | — | US | claimed |
| CN-107708665-B | Pharmaceutical tetracycline compositions for dermatological use | 贝尔生物制药有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-10881672-B2 | Pharmaceutical tetracycline composition for dermatological use | BioPharmX, Inc. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-3273940-B1 | PHARMACEUTICAL TETRACYCLINE COMPOSITION FOR DERMATOLOGICAL USE | BIOPHARMX INC (US) | 2020-12-16 | — | — | EP | disclosed |
| US-20200046739-A1 | PHARMACEUTICAL TETRACYCLINE COMPOSITION FOR DERMATOLOGICAL USE | BioPharmX, Inc, | 2020-02-13 | — | — | US | disclosed |
| US-10391108-B2 | Pharmaceutical tetracycline composition for dermatological use | BioPharmX, Inc. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180185394-A1 | PHARMACEUTICAL TETRACYCLINE COMPOSITION FOR DERMATOLOGICAL USE | LEO PHARMA A/S (DK) | 2018-07-05 | — | — | US | disclosed |
| CN-101693669-B | minocycline hydrochloride hydrate crystal form and preparation method thereof | UNIV ZHEJIANG | 2012-08-08 | — | — | CN | disclosed |
| CN-101693669-B | minocycline hydrochloride hydrate crystal form and preparation method thereof | UNIV ZHEJIANG | 2012-08-08 | — | — | CN | disclosed |
| CN-102617396-A | Minocycline hydrochloride hydrate crystal form and synthesis method thereof | UNIV ZHEJIANG | 2012-08-01 | — | — | CN | disclosed |
| CN-102617396-A | Minocycline hydrochloride hydrate crystal form and synthesis method thereof | UNIV ZHEJIANG | 2012-08-01 | — | — | CN | disclosed |
| CN-101693669-A | Minocycline hydrochloride hydrate crystal form and preparation method thereof | UNIV ZHEJIANG | 2010-04-14 | — | — | CN | disclosed |
| CN-101693669-A | Minocycline hydrochloride hydrate crystal form and preparation method thereof | UNIV ZHEJIANG | 2010-04-14 | — | — | CN | disclosed |
| US-20040253314-A1 | Melt extrusion of salts of active ingredients | ROEHM GMBH (DE) | 2004-12-16 | — | — | US | disclosed |